Tekmira and Protiva complete business combination
As part of the business combination, a $10 million private placement with Alnylam Pharmaceuticals and an affiliate of F Hoffman-La Roche has also been completed at a price
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
Lenalidomide was intended for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality. The marketing